Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05675449
Title A Clinical Trial of Three Medicines (Elranatamab Plus Carfilzomib and Dexamethasone) in People With Relapsed Refractory Multiple Myeloma (MagnetisMM-20)
Acronym MagnetisMM-20
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Pfizer
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ISR


No variant requirements are available.